---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-104564"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2024-09-09T23:59:59+00:00"
generated_at: "2026-05-31T05:56:16.870867+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SAB Bio completes Phase 1 healthy-volunteer enrollment; SAB-142 shows no serum sickness at 2.5 mg/kg

## Summary
- Phase 1 trial of SAB-142 for type 1 diabetes completed all planned healthy-volunteer cohorts; no serum sickness observed at target 2.5 mg/kg dose.
- Company now enrolling type 1 diabetes patients in the last cohort of the Phase 1 study.
- Topline Phase 1 data readout expected by end of 2024.
- SAB-142 is a first-in-class human anti-thymocyte immunoglobulin with differentiated safety profile compared to rabbit ATG.

## SEC filing metadata
- accession: 0000950170-24-104564
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2024-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017024104564/0000950170-24-104564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017024104564/sabs-20240909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-104564
- JSON: https://secwatch.observer/filing/0000950170-24-104564.json
- Plain text: https://secwatch.observer/filing/0000950170-24-104564.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.